Look at the way the Boston Globe approached this story compared to the Wall Street Journal. The difference is subtle but important. The Journal focused too narrowly on the idea that patients might be able to avoid cleansing their colons before going in to get a computer scan of their intestines. The Globe, under the same deadline pressure, placed the new research into the larger context of the growing but complicated array of methods to detect colon cancer and precancerous polyps early.
The Globe rightly points out that colonscopy is not the only option for people hoping to catch cancer early. This is crucial for readers to have a clear understanding of screening and prevention options. The Wall Street Journal got the news out first, but the Globe provided readers better information.
The story mentioned costs and insurance coverage, while the Wall Street Journal story on the same topic mentioned neither. The Globe wrote, “Medicare doesn’t provide coverage for the imaging test, which Zalis said costs about one-third as much as the traditional scope screening.”
The lead of the story says, “A new method of performing virtual colonoscopy using a CT scan — which doesn’t involve the dreaded laxative preparation to clear the colon the night before — may be about as effective as a standard colonoscopy at identifying the large polyps most likely to become cancerous, according to research conducted at Massachusetts General Hospital, Brigham and Women’s Hospital, and elsewhere.” Later, it amplifies this claim by providing the numbers from the study: “In the study of 605 patients, published Monday in the Annals of Internal Medicine, the prep-free virtual colonoscopy was able to identify more than 90 percent of suspicious polyps that were 10 millimeters or larger, compared with 95 percent identified when the same patients later had a standard colonoscopy.” It also provided some data to back up the statement found in the story that, “Surveys suggest that patients find the prep — required for both colonoscopy and traditional virtual colonoscopy — to be the worst part of screening.” The story said, “Of the study participants who expressed a preference, 62 percent said they preferred the prep-free CT procedure over the colonoscopy.”
What this story did that a Wall Street Journal story on the same topic failed to do as thoroughly was explain the potential harms – both from virtual colonoscopy and the traditional methods. It said, “Virtual colonoscopy, with or without prep, has some limitations. About one in five patients must undergo a standard colonoscopy after the imaging procedure to have suspicious looking polyps snipped off and biopsied. The CT scan also delivers a dose of radiation that — while only one-fifth of the dose of an abdominal CT scan — was significant enough to raise the flags of the US Preventive Services Task Force. The government advisory group decided in 2008 not to recommend the use of virtual colonoscopy, saying that evidence wasn’t sufficient enough to prove that the test’s benefits outweighed its harms, which include a dose of radiation with every screening test. (Standard colonoscopy also has rare complications such as an adverse reaction to the sedative, perforation to the colon, and bleeding from the site where the polyp was taken.)” We rarely see this level of detail in a piece, and it shows what a reporter who has command of the topic can do in a relatively small amount of space.
The Globe did a nice job explaining the mechanics of the study. But it didn’t include any discussion of the limitations of the research, as MedPage Today reported:
The researchers cautioned that they had only three people reading all the images in the study and there were variations in their performance.
Other limitations were the size of the study and the quality of the survey data.
“Restricting study to a low-risk cohort limited the prevalence of lesions and the study’s statistical power, especially for polyps 10 mm or larger,” they added.
The story did not engage in disease mongering. Instead, it pointed out both the number of Americans who are not properly screened and the range of available options for screening, saying, “Only one in six Americans over age 50 get the American Cancer Society’s recommended screening for colon cancer: a colonoscopy every 10 years, or a flexible sigmoidoscopy, virtual colonoscopy, or barium enema imaging every five years.”
The story quoted Dr. Durado Brooks, director of prostate and colon cancer for the American Cancer Society. It also noted high in the story that the research “was partially funded by GE Healthcare, manufacturer of the CT imaging device.” It would have been worth noting — as the Wall Street Journal did — that the author quoted in the piece also developed the software involved, which could make the success of this type of screening profitable for him.
First and foremost, the story mentions alternatives to colonoscopy, while other coverage of the same study failed to mention alternatives. It also explains why US Preventive Services Task Force has decided against recommending virtual colonoscopy. The Wall Street Journal, by comparison, wrote that the advent of virtual colonoscopy had eliminated the need for traditional scoping. The Globe also says, “Traditional colonscopy also trumps the virtual test when is comes to detecting smaller polyps, less than 10 millimeters in size. The new study found that virtual colonosopy detected only 70 percent of polyps under 8 millimeters in size, compared with 88 percent detected by a scope. What’s not clear, though, is whether missing these smaller polyps will make a difference in terms of catching growths before they turn into cancer.”
The story makes it clear that this is a technique that is in the testing phase, saying, “If the finding is confirmed by larger studies, the technique could eventually serve as a first-line screening tool for colon cancer, especially for the many people who avoid screening altogether.”
The relative novelty of the approach – using a contrast agent which can then be digitally erased from the scan using a computer software program – was clear in the story.
The story does not rely on a press release.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like